胰腺癌（PC）通常在其发展的晚期被诊断出来，这导致整体生存率（OS）较低。即使进行了有治愈意向的手术，预后也较差。在诊断时，约80%的局部PDAC患者存在微转移，这导致与其他癌症相比预后更差。本研究的目标是根据ESMO、NCCN、ASCO、NICE和SEOM等肿瘤科学学会的建议，介绍过去5年中转移性胰腺癌治疗的进展。对于病情良好的患者，联合FOLFIRINOX疗法通常是推荐的治疗方法，而对于更脆弱的患者，吉西他滨被推荐为一线治疗。最新的指南建议，肿瘤的分子分析应是确定治疗方案的第一步。在具有特定基因突变的患者中使用现代分子疗法应该能延长这种疾病的患者的生存期。

Pancreatic cancer (PC) is usually diagnosed at an advanced stage of its development, which results in lower overall survival (OS). Prognosis is also poor even with curative-intent surgery. Approximately 80% of patients with localized PDAC have micrometastases at the time of diagnosis, which leads to a worse prognosis than in other cancers. The objective of this study is to present the progress in the treatment of metastatic pancreatic cancer based on the recommendations of oncological scientific societies, such as ESMO, NCCN, ASCO, NICE and SEOM, over the last 5 years. Combined FOLFIRINOX therapy is mostly a recommended therapy among patients with good performance statuses, while gemcitabine is recommended for more fragile patients as a first-line treatment. The newest guidelines suggest that molecular profiling of the tumor should be the first step in determining the course of treatment. The use of modern molecular therapies in patients with specific gene mutations should extend the survival of patients with this disease.